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C HILDREN WITH Down syndrome (DS) are known to
develop acute leukemia more frequently (1 in 100 to 200 children), and children younger than 4 years usually develop acute myeloid leukemia (AML; 1 in 300). In the 1960s and 1970s, children with DS and AML were believed to have excessive toxicity with chemotherapy, so few were treated. 1 It was not until the 1980s that many children with DS were enrolled in cooperative group trials. Though study accrual numbers were small, the experience with children with DS on those trials was reported, and, surprisingly, suggested that despite continuing trends toward having more toxicity, this population had similar survival outcomes compared with the children without DS. 2 In the 1990s, the Children's Cancer Group (CCG) reported the largest single study in which children with DS and AML were treated. 3 Our current report expands on the earlier report with longer follow-up of the original cohort of children, 3 more enrolled children who were treated uniformly on the standard timing chemotherapy arm, analysis of prognostic factors, and examination of toxicity and relapse in patients with DS, by focusing on a cohort treated uniformly with standardtiming conventional chemotherapy without bone marrow transplantation (BMT).
PATIENTS AND METHODS
CCG-2891, a phase III randomized trial, compared intensively timed induction therapy with standard conventionally timed induction therapy. We compared postremission intensively timed high-dose cytarabine-based chemotherapy with 4HC-purged autologous BMT or matched related allogeneic BMT. 4 Patients eligible for CCG-2891 were aged 0 to 20 years, with untreated AML or myelodysplastic syndrome. Patients or their legal guardians signed informed consent forms approved by local institutional review boards and in compliance with the Declaration of Helsinki. Between October 12, 1989, and October 15, 1999, 1,202 children were registered onto CCG-2891 (947 patients without DS, 190 with DS, and 65 excluded for various reasons). Accrual for patients without DS ended in 1994. The characteristics and methods of this study were reported previously. 4 ,5 Acute myeloid leukemia and myelodysplastic syndrome were classified according to the French-American-British (FAB) criteria. [6] [7] [8] [9] For this analysis, the definition of myelodysplastic syndrome was limited to 29% or fewer blasts present in the bone marrow (BM) sample. Morphology, histochemistry, and institutional immunophenotype reports were reviewed centrally. When central review was not available, institutional results were used. Methods and concordance have been described elsewhere. 10 Together, central and institutional review allowed the histologic FAB classification of 151 (94%) of 161 total DS patients (M0-M7, RA, RAEB, and RAEB-T). In determining the FAB classification, 21 of 88 patients diagnosed with FAB M7 AML had bone marrow blast percentages less than 30%. When interim analyses as of July 18, 1992, showed excessive toxicity in children with DS, we excluded those children first from allogeneic BMT, and then from autologous BMT and intensively timed induction. Thereafter, children with DS were assigned nonrandomly to standard-timing induction followed by postremission chemotherapy (Fig 1) . Because three fourths of the children with DS had treatment assigned, we report "as-treated" analyses rather than "intent-totreat" analyses. In the patients without DS, the intent-to-treat and as-treated analyses are essentially identical. 4 The chemotherapy regimen for induction has been described, and includes cytarabine 200 mg/m 2 /d, daunorubicin 20 mg/m 2 /d, etoposide 100 mg/m 2 /d, dexamethasone 6 mg/m 2 /d, and 6-thioguanine 100 mg/m 2 /d. Cytarabine, daunorubicin, and etoposide were given by continuous intravenous infusion, and dexamethasone and 6-thioguanine were given orally. All medications were given on days 0 to 4 of each of four induction cycles. The patients who had standard-timing induction received each subsequent induction cycle on blood count recovery from the preceding cycle. Patients were assessed for response on day 7 of induction cycle 1, and for remission at the end of induction cycles 1 and 4, with the end of cycle 4 being defined as the end of induction. The postremission intensification phase of therapy consisted of 3-hour infusions of cytarabine 3,000 mg/m 2 given every 12 hours on days 0 through 1 and 7 through 8, and L-asparaginase 6,000 U/m 2 given once intramuscularly on days 1 and 8. Afterwards, patients went on to receive 3 months of relatively low-dose maintenance chemotherapy as described. [3] [4] [5] This report summarizes analyses of data obtained in CCG-2891 through August 2000. We tested the significance of observed differences in proportions using the 2 test and Fisher's exact test when data were sparse. For continuous data, we used the Mann-Whitney test to compare the medians of skewed distributions.
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We calculated estimates of overall survival (OS), event-free survival (EFS), and relapse-free survival (RFS) using the Kaplan-Meier method.
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EFS is defined as time from study enrollment to induction failure, marrow relapse, or death. We defined RFS as time from induction remission (end of induction cycle 4) to marrow relapse or death caused by progressive disease, censoring deaths from other causes. Patients lost to follow-up were censored at their last known points of study, with a cutoff of February 11, 2000. We calculated confidence intervals with Greenwood's formula. 13 Differences in OS and EFS were tested for significance with the log-rank statistic. 14 Incidence of relapse after remission was estimated as cumulative incidence, with death and other competing risks censored. 15 Factors significant in univariate analysis at P Ͻ .05 were considered for inclusion in multivariate models. We used Cox regression to construct multivariate survival models. 16 The likelihood ratio test was used to determine whether variables should be added or dropped from the multivariate model. Multivariate analyses included patients with complete covariate data.
RESULTS
Between 1989 and 1999, 190 children with DS were enrolled onto CCG-2891. We excluded patients who were treated on the intensive timing induction arm (n ϭ 20) or who received BMT (n ϭ 9) from this analysis, leaving 161 patients who were treated on the standard timing induction arm followed by chemotherapy intensification, Capizzi II, if induction remission was achieved. These 161 patients did not receive a BMT regardless of the availability of matched siblings. Table 1 provides the presenting characteristics of the children with DS and the characteristics of those without DS. Children with DS were significantly younger at AML/MDS diagnosis than those without DS. At AML/MDS diagnosis, only 2% of children with DS were older than 5 years, whereas 61% of children without DS were older than 5 years. Patients with DS presented with AML/MDS significantly earlier than those without DS. Among DS children alone, no significant difference in age incidence between those diagnosed with AML (1.86 years) or MDS (1.81 years) was identified (P ϭ .222). A larger percentage of children with DS were nonwhite, but this was not statistically significant. Hepatomegaly (P ϭ .02) and splenomegaly (P ϭ .06) were seen in a significantly greater percentage of patients with DS, whereas adenopathy (P Ͻ .001) was seen significantly less often in DS children. Evidence of CNS disease (CSF or cranial nerve involvement) was relatively rare in those with DS compared with those without DS. Hyperleukocytosis (WBC count Ͼ 100,000/mm 3 ) was very rare among the patients with DS, and median WBC count at diagnosis was significantly lower than in patients without DS. Patients with DS also had significantly lower platelet levels at diagnosis.
Patients With DS Versus Those Without DS
Pathological characteristics of patients' diagnostic BM examinations are presented in Table 1 . Among the 161 patients with DS, 66% had 30% or more blasts in the marrow, meeting the traditional criteria for an AML diagnosis. At diagnosis, 34% of 
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patients with DS had less than 30% BM blasts; of that group, 32% had refractory anemia with excess blasts or refractory anemia with excess blasts in transformation, with 5% to 30% blast concentration in the marrow, and 2% had refractory anemia with less than 5% marrow blasts. Among those patients with FAB classification designations of M0 to M7 (n ϭ 125), acute megakaryocytic leukemia (FAB M7) was diagnosed most often (70%), while FAB M0 AML was the next most common FAB Histochemical staining characteristics of leukemic blasts from patients with DS were significantly different from those without it, and reflected the differences in FAB types between the two populations. Auer rods were seen in only 3% of children with DS, compared with 38% in those without DS (data not shown; P Ͻ .001). Cytogenetic abnormalities also reflected differences in FAB distribution; t(8;21) was not diagnosed in any patient with DS. Flow cytometry results showed a significant proportion of patients with DS who had the T-cell cell surface marker CD7 (81%), which was much less common in patients without DS (29%; P Ͻ .001). Antiplatelet glycoprotein positivity also was found in a higher percentage of patients with DS, corresponding with the higher percentage of patients with FAB M7. CD15 blast positivity was found significantly less often in the patients with DS.
To study tolerance of treatment regimens, we collected information on the incidence of grade 3 or 4 toxicity in patients with and without DS who received standard induction and chemotherapy intensification (Table 2 ). Comparing tolerance of standard timing induction regimens in children with and without DS revealed no significant differences in overall toxicity (P ϭ .84). One significant difference during standard timing induction was a significantly higher rate of pulmonary toxicity among children with DS (P ϭ .004). This difference was primarily during the first course of induction (9.3% v 2.8%). When limiting this to only functional pulmonary toxicity (oxygen or assisted ventilation required), the difference between children with and without DS remained significant (P ϭ .005). Examination of the intensification phase, in which intensively timed high-dose cytarabine was used, revealed that the phase was tolerated equally well in both populations, with no difference in cumulative incidence of grade 3 or 4 toxicities (P ϭ .31), although there were some significant differences in certain organ toxicities during this phase of therapy (Table 2) .
Children with DS had better overall survival and EFS, primarily due to a better remission induction rate and a significantly lower relapse rate posttherapy. More children with DS had CR after induction (91%) than those without DS (75%; P Ͻ .001; Table 1 ). During induction, the rate of remission failure in the children with DS was 6%, compared with 25% in children without DS who had standard timing, and 12% in those who had intensive timing (P Ͻ .001). Children with DS had improved cumulative relapse rates (Fig 2) and toxic death rates compared with those without DS. During intensification, there was no difference in relapse rates between children with (7%) and without DS (11%; P was not significant) who received chemotherapy.
Toxic mortality during induction in children with DS was 3%, compared with children without DS who received standard timing (4%), and those who had intensive timing (9%; P Ͻ .001). During intensification, children with DS had a slightly lower toxic mortality (1%) than children without DS (5%; P ϭ .04).
Survival among the children with DS was better (6-year OS, 79%; 6-year EFS, 77%) than in children without DS (6-year OS, 43%; 6-year EFS, 33%; P Ͻ .0001). Survival rates for children with DS were better than for children without it, regardless of induction timing (Fig 3) . Children with DS who had CR had better RFS from the end of induction (86%) than children without DS who were in CR at the end of induction, and who had intensive (57%) or standard (38%) induction (P Ͻ .001). These rates were better, though they included children with DS who received the chemotherapy intensification only, compared with children without DS who received either chemotherapy or transplantation for their intensification therapy.
Acute Megakaryocytic Leukemia-Restricted Analysis: Children With DS Versus Those Without It
We then analyzed data of children with FAB M7 AML, to elucidate differences between M7 AML in children with DS (n ϭ 88) and children without it (n ϭ 54). Both groups had young median ages at presentation, (children with DS, 1.9 years; children without DS, 2.1 years; P ϭ .558). We analyzed variables among physical examination findings at diagnosis. Only hepatomegaly and splenomegaly were significantly different, being more common in M7 children with DS (55% and 57%, respectively) than in children without it (33% and 35%; P ϭ .02). At diagnosis, blasts were seen rarely in the CSF of children with DS and M7 AML (6%), compared with those with M7 AML but not DS (16.7%; P ϭ .08). No clinical laboratory findings at diagnosis were significantly different between the children with M7 AML who did and did not have DS (data not shown). There were also no differences in diagnostic cytogenetics. When examined for the lymphoid lineage antigen CD7, leukemic blasts in children with M7 AML with DS were significantly different from blasts in those without it. At diagnosis, CD7 was present in 79% of children with DS compared with only 40% in children without DS (P Ͻ .001). The rapidity of response (BM blasts Ͻ5%) was significantly greater in children with DS and FAB M7 as measured by the day 7 BM examination (84% v 55%; P ϭ .003) and as measured by the end-of-induction remission rate (92% v 64%; P ϭ .003). Sixyear OS (81% v 31%; P Ͻ .0001) and EFS (78% v 28%; P Ͻ .0001) were significantly better among the patients with DS and FAB M7 than among patients with FAB M7 but not DS. Finally, children with DS who had FAB M7 leukemia had a 6-year EFS of 78% compared with DS children with other FAB types (71%; P was not significant).
DS-Restricted Analysis: Prognostic Factors
Because of the large number of patients with DS enrolled in this study, we could examine factors that predict EFS. All items presented in Table 1 were reviewed. In univariate analysis, only age at the time of diagnosis (P ϭ .002) and rapidity of response (day-7 BM result; P ϭ .03) were predictive of EFS. In multivariate models (Table 3) , only age was predictive of EFS. Children with DS who were older than 2 years at diagnosis had a five-fold greater chance of adverse outcome than those who were age 2 years or younger when fit with the day-7 BM examination (P ϭ .006). Children with DS who were age 2 years or younger had a 6-year EFS of 86% compared with those older than 2 years who had a 6-year EFS of 64% (P ϭ .002). While less statistically significant, slower response (odds ratio, 2.6; P ϭ .07) independently trended toward a greater risk of adverse outcome. As in the early analysis of CCG-2891, the 6-year EFS of children with DS and myelodysplastic syndrome was as good (78%) as that for children with DS with AML (76%; P was not significant).
DS-Restricted Analysis: Age-Related Comparison
We divided the children with DS into two age groups to test whether age at diagnosis affected outcome. Table 4 presents statistically significant characteristics based on age. Median age of those Յ 2 years was 1.44 years, and the median age of those older than 2 years was 2.65 years. Only 23 patients (14%) were older than 36 months, and nine patients (6%) were older than 48 months. Presenting physical and laboratory findings generally were no different, except for two (enlarged lymph nodes and percent of population with WBC count Ͼ 20,000) that suggested greater tumor burden in older children at diagnosis. Whereas median WBC count at diagnosis did not differ (age Յ 2 years, 6,700 v age Ͼ 2 years, 7,700; P ϭ .23), the presenting WBC count was skewed towards higher values in older children. Leukemic blast characteristics showed no difference in the prevalence of FAB types. Fewer younger children had FAB M7 morphology (66.7% v 75.5%; P ϭ .29), and more had FAB M0 (11.1% v 5.7%; P ϭ .35), but neither was statistically significant. 
AGE IMPACT IN AML CHILDREN WITH DOWN SYNDROME
Flow cytometric analysis of leukemic cells showed that CD2 (30.3% v 10.4%; P ϭ .01) and CD7 (86.8% v 72.9%; P ϭ .09), typically T-cell markers, were found more often in leukemic blasts of younger patients. There was no difference in antiplatelet glycoprotein leukemic blast expression (expression defined as Ͼ25%) between age groups (P ϭ .99). Chromosomal translocations were not significantly different between groups, though there was a trend toward more monosomy 7 in older children (18.5% v 5.9%; P ϭ .117). That trend did not have an independent effect from age on EFS because just two of eight children with DS and monosomy 7 had relapses. Toxicity comparisons by age were examined by phase of therapy and showed no statistically significant excess toxicity in either age group (data not shown).
Older patients were less likely to have achieved CR by the end of the first induction course (77.2% v 89%; P ϭ .096). Significantly fewer older children with DS had successful outcomes at the end of induction (85% v 96%; P ϭ .023), primarily due to lack of remission (14% v 1%; P ϭ .002) rather than toxicity. There was no significant difference in causes of death during induction. The 6-year EFS was significantly better for younger (86%) than for older patients (64%; P ϭ .002). Figure 4 , which illustrates survival by age at diagnosis, identifies that poorer outcome in older children is a stepwise progression with worse outcome in each older cohort, ages 0 to 2 years, 2 to 4 years, and older than 4 years (though the numbers in the last group are small; n ϭ 9). There was a statistically worse EFS in the 2 to 4 year old group compared with younger children, which was quite strong when we compared the 0-to 4-year-olds to the few patients older than 4 years.
DISCUSSION
This analysis represents the largest cohort reported to date of DS patients with AML or myelodysplastic syndrome treated on a uniform protocol (n ϭ 161 patients). Due to the size of this cohort, this is the first study in which examination of prognostic risk factors, in addition to diagnostic and outcome characteristics of patients, has been possible.
This study confirms the findings in prior series of children with DS and myeloid leukemias that identified unique characteristics not found in children without DS who have AML, including megakaryoblastic predominance, [17] [18] [19] increased CD7 expression, 18,19 high percentage of patients with myelodysplasia, 19 and younger age at diagnosis. [17] [18] [19] [20] [21] [22] This study additionally found that CNS involvement was relatively rare in the DS population (5% v 20% without DS; P Ͻ .001), a finding similar to prior observations that did not have enough patients to draw statistical conclusions. 18, 19 This finding may reflect the generally lower total WBC counts at diagnosis, an association previously recognized. 23 Examination of this large population confirmed several smaller series 18, 19, 22, 24, 25 that found patients with DS had improved outcomes compared with patients without DS treated with similar or more intensive therapy. This improved outcome was a result of significantly greater remission rates, equivalent or lower toxicity, and less subsequent relapse when they were 0-5% (n ϭ 73) 1.0 Ͼ 5% (n ϭ 12) 2.6 0.9 to 7.5 .07 NOTE. Multivariate model listed above includes those variables that were found to be significant in univariate analysis and remained so in multivariate analysis. Not all data were available for every patient, and therefore, the sample size is less than the total enrolled (complete data; n ϭ 85). (Tables 1 and 2 ; Fig 2) . The size of this cohort of DS patients has permitted analysis of prognostic factors. Several poor prognostic factors found in children with AML without DS had either no effect on our DS patients' outcomes or were not seen in this cohort. Monosomy 7, slightly more prevalent in this cohort of DS children than the children without DS (10.3% v 6.1%; P ϭ .217), did not have a significant effect on CR (Table 1) or EFS (EFS: monosomy 7 present, 63% v absent, 82%; P ϭ .173). Only one patient with DS had a WBC count more than 100,000, and thus no effect of high WBC count could be analyzed. WBC count greater or less than 20,000 had no effect on prognosis (78% v 72%; P ϭ .31).
We found that among the characteristics identified to be unique to the DS population of myeloid leukemia patients, only age at diagnosis had independent prognostic significance (odds ratio, 4.9), primarily a result of poor remission induction in older patients (Table 3) . It is known that children with DS have a greater risk of developing leukemia, 24 and myeloid leukemia in particular. 22 As with other congenital cancer predispositions, the unique age distribution of myeloid leukemias in children with DS is skewed towards earlier age at diagnosis. Children with DS in this study were significantly younger than those without DS (median age, 1.8 v 7.5 years; P Ͻ .001), so much so that only 2% of the cohort were older than 5 years at diagnosis.
As age was the only significant prognostic indicator, examination of the differences between the younger and older DS patients was undertaken (Table 4) . Examination into characteristics of the leukemia present in the two age groups found few differences. The leukemia found in the older children tended to be associated with more bulk disease and less expression of the typically T-cell markers, CD2 and CD7. Whether this represents some fundamental difference between the types of leukemia not discernable by histologic or cytogenetic differences is unknown and requires further study. As the one factor other than age that approached an independent prognostic level in overall DS population was reduction of BM blasts to less than 5% by day 7 of induction, a difference in leukemia cell chemosensitivity or a difference in chemotherapy metabolism might be considered. While there was no difference between the age groups in rapidity of BM blast clearance measured on day 7 (data not shown), there was a significantly worse induction of remission for older DS patients. The possible causes for the poorer remission rate in older DS children were either an increase in toxic mortality or more patients with persistent leukemia at the end of induction. Data indicate the latter.
Increased toxic complications among patients with DS have been reported by several investigators, 2, 19, 24, 26 and were presumed to be caused by increased chemosensitivity. This current trial found that when dose-intensity was decreased instead of absolute dose, toxicity in the entire cohort of patients with DS was no worse than in patients without DS. In the younger DS cohort this reduction of toxicity was achieved without worsening remission rates at the end of induction and without worsening subsequent RFS (Fig 4) . In the older DS patients there appeared to be less chemosensitivity illustrated by the combination of a greater risk of persistent leukemia at the end of induction, combined with the absence of increased toxicity.
Further, the dose-intensity of the intensively timed intensification that followed induction caused no significantly greater toxicity in patients with DS than in those without it nor was there greater toxicity during this phase in the older than in the younger DS cohort. Several reports have also suggested that high-dose cytarabine affects survival in patients with DS and is relatively well tolerated. 18, 19, 26 All patients on our trial received high-dose cytarabine, which prevented randomized evaluation of its benefit, but the excellent outcomes appear to confirm that it did not reduce efficacy or cause excessive toxicity despite its intensive timing. CCG-2891 examined the effect of increasing dose-intensity through the administration of identical doses in either rapid sequence before blood count recovery (on the intensive timing arm) or in standard monthly pulses after blood count recovery (standard timing arm). It is difficult to determine whether therapeutic regimens administered with prior trials would result in a better outcome for older DS patients than that seen with the standard timing chemotherapydexamethasone, cytarabine arabinoside, 6-thioguanine, etoposide, daunorubicin (DCTER). A review of these trials finds that few of those enrolled were in this older, apparently high-risk age group identified in this study. 18, 19, 21 This study, in combination with this trial's earlier analysis of the intensive timing arm patients, 3 suggests that older children with DS and AML or MDS require a more intensive induction than found in standard timing 4 day DCTER but less than that found in the intensively timed DCTER. Future studies should include examination of the impact of age on remission induction and RFS to confirm these findings. In addition, further analysis of the leukemia in the two age cohorts (eg, prevalence of Flt3 ligand and minimal residual disease as measured by new techniques) may more accurately identify risk factors that cosegregate with age.
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